Comparasion of efficacy and safety of Difluprednate 0.05% and Nepafenac 0.1% in reducing macular thickness and volume after cataract surgery
Objective- To evaluate and compare efficacy and safety of topical Difluprednate ophthalmic emulsion 0.05% with Nepafenac ophthalmic suspension 0.1% in patients of uneventful cataract surgery with respect to postoperative macular thickness and volume.
Design- A prospective, single centric, tertiary care centre based, comparative, interventional study from August 2013 to July 2014
Subjects- Total 206 ( Group N=106, Group D=100) patients were followed up who completed their 12 weeks follow up
Methodology- Surgery was performed by phacoemulsification technique by clear corneal incision with foldable PCIOL implantation by a single surgeon having 10 years of surgical experience. Post operative patients were divided into 2 groups. Group N were given topical treatment with Nepafenac ophthalmic suspension 0.1% TID starting 24 hours before surgery and continued post-op 4 weeks. Group D were given Difluprednate ophthalmic emulsion 0.05% QID post surgery for 2 weeks followed by BID for 2 weeks.
Main outcome measures: Postoperative assessment of patients were done on 1st day and on 1st, 8th and12th weeks after the surgery for best corrected visual acuity (BCVA) by logMAR, intraocular pressure by Applanation tonometry and macular thickness and volume by SD-OCT. Statistical test used was sample Unpaired and paired ‘t’ test and statistical analysis was done with SPSS 20.0 ( IBM, USA).
Results- There was increase in the measured mean central subfield thickness( CST) at 8 and 12 weeks as compared to 1 week , in both the study groups (P<0.05). On comparing the volume (in mm3) and average thickness (in µm) at 1 week, it was observed that thickness of group N (266.82±25.06 µm) was statistically higher than that of group D (253.14±22.21µm) (P= 0.03). The comparison of best corrected visual acuity (LogMAR) and the intraocular pressure recordings showed no difference between the patients of two studied groups recorded at 1 week and 8 weeks and 12weeks.
Conclusion- Both Nepafenac ophthalmic suspension 0.1% and Difluprednate ophthalmic emulsion 0.05% are equally effective in controlling macular thickness change after uneventful cataract surgery.
2. Flavia LB, Shyam SC, Alicia C, et al. Corneal myofibroblast generation from bone marrow-derived cells. Exp Eye Res 2010;91:92-96.
3. Chan T, Payor S, Holden BA. Corneal thickness profiles in rabbits using an ultrasonic pachometer. Invest Ophth Vis Sci 1983;24:1408-1410.
4. Fantes FE, Hanna KD, Waring GO, et al. Wound healing after excimer laser keratomileusis (photorefractive keratectomy) in monkeys. Arch Ophthalmol 1990;108:665-675.
5. Gu S, Xing C, Han J, Tso MOM, Hong J. Differentiation of rabbit bone marrow mesenchymal stem cells into corneal epithelial cells in vivo and ex vivo. Mol Vis 2009;15: 99.
6. Yosuke H, Waka I, Ken F, et al. Identification of keratocyte-like cells differentiated from circulating bone marrow-derived cells in the mouse cornea. Med Mol Morphol 2013;46:233-238.
7. Kamran H, Alexander IK, Irina YP, et al. Monitoring of rabbit cornea response to dehydration stress by optical coherence tomography. Invest Ophth Vis Sci 2004;45:2555-2562.
8. Yanling M, Yongsheng X, Zhifeng X, et al. Reconstruction of chemically burned rat corneal surface by bone marrow–derived human mesenchymal stem cells. Stem Cells 2006;24:315-321.
9. Norzana AG, Ropilah AR, Jemaimah C, et al. Rabbit limbal epithelial cells maintain its stemness in serum-free and feeder layer-free culture system. Tissue Eng Regen Med 2007;4:557-565.
10. Joo YO, Mee KK, Mi SS, et al. The anti-inflammatory and anti-angiogenic role of mesenchymal stem cells in corneal wound healing following chemical injury. Stem Cells 2008;26:1047-1055.
11. Soo HP, Kyoung WK, Yeoun SC, Jae CK. Human mesenchymal stem cells differentiate into keratocyte-like cells in keratocyte-conditioned medium. Exp Eye Res 2012;101:16-26.
12. Rohaina CM, Then KY, Angela NMH, et al. Reconstruction of limbal stem cell deficient corneal surface with induced human bone marrow mesenchymal stem cells on amniotic membrane. Transl Res 2014;163:200-210.
13. Wakitani S, Goto T, Pineda SJ, et al. Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage. J Bone Joint Surg Am 1994;76:579-592.
14. Ye J, Yao K, Kim JC. Mesenchymal stem cell transplantation in a rabbit corneal alkali burn model: engraftment and involvement in wound healing. Eye 2005;20:482-490.
Copyright (c) 2016 Asian Journal of Ophthalmology
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication, with the work twelve (12) months after publication simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).